Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity.
The present studies examined the role of endogenous dopamine (DA) in methamphetamine (METH)-induced dopaminergic neurotoxicity while controlling for temperature-related neuroprotective effects of the test compounds, reserpine and alpha-methyl-p-tyrosine (AMPT). To determine if the vesicular pool of DA was essential for the expression of METH-induced DA neurotoxicity, reserpine (3 mg/kg, given iintraperitoneally 24-26 h prior to METH) was given prior to a toxic dose regimen of METH. Despite severe striatal DA deficits during the period of METH exposure, mice treated with reserpine prior to METH developed long-term reductions in striatal DA axonal markers, suggesting that vesicular DA stores were not crucial for the development of METH neurotoxicity, but leaving open the possibility that cytoplasmic DA might be involved. To evaluate this possibility, cytoplasmic DA stores were depleted with AMPT prior to METH administration. When this study was carried out at 28 degrees C, complete neuroprotection was observed, likely due to lingering effects on core temperature because when the same study was repeated at 33 degrees C (to eliminate AMPT's hypothermic effect in METH-treated animals), the previously observed neuroprotection was no longer evident. In the third and final set of experiments, mice were pretreated with a combination of reserpine and AMPT, to deplete both vesicular and cytoplasmic DA pools, and to reduce striatal DA levels to negligible values during the period of METH administration (< 0.05%). When core temperature differences were eliminated by raising ambient temperature, METH-induced DA neurotoxic changes were evident in mice pretreated with reserpine and AMPT. Collectively, these findings bring into question the view that endogenous DA plays an essential role in METH-induced DA neurotoxicity.
Yuan
J
J
Departments of Neurology and Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA.
Callahan
B T
BT
McCann
U D
UD
Ricaurte
G A
GA
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D001923:Brain Chemistry / Q000502:physiology*; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D018765:Dopamine Uptake Inhibitors / Q000633:toxicity*; D008297:Male; D008694:Methamphetamine / Q000633:toxicity*; D051379:Mice; D020258:Neurotoxicity Syndromes / Q000473:pathology*; D012110:Reserpine / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology; D019805:alpha-Methyltyrosine / Q000494:pharmacology
D018765:Dopamine Uptake Inhibitors; D013565:Sympatholytics; D015102:3,4-Dihydroxyphenylacetic Acid; D008694:Methamphetamine; D019805:alpha-Methyltyrosine; D012110:Reserpine; D004298:Dopamine